Novocure Limited · NASDAQ:NVCR

Novocure — Q2 2025 Earnings Presentation

13 slides from Novocure's earnings presentation, Jul 24, 2025

  1. Slide 1: Novocure GmbH

    Confidential © 2024 Novocure © 2025 GmbH Novocure GmbH 1

  2. Slide 2: Forward-looking statements

    novecure’ forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding

  3. Slide 3: © 2025 Novocure GmbH 3

    ✓ ✓ ✓ • • ✓ • • • • © 2025 Novocure GmbH 3

  4. Slide 4: 2025 Novocure GmbH 4

    • • • • © 2024 2025 Novocure GmbH 4

  5. Slide 5: Promising returns in non-small cell lung cancer launch

    novecur promising returns in non-small cell lung cancer launch RIGHT PHYSICIAN RIGHT PATIENT RIGHT TIME PRESCRIBER BREADTH. BROAD LABEL USE QUICK STARTS 121 NEW ADOPTERS PRIOR ICI USE EARLIER LINES 94 entforward’ Unless otherwise denoted, all prescriber, prescription, and patient statistics are refl

  6. Slide 6: PANOVA-3: first phase trial to extend OS in unresectable, locally advanced pancreatic cancer

    novecure’ PANOVA-3: first phase 3 trial to extend OS in unresectable, locally advanced pancreatic cancer OVERALL SURVIVAL 1.0 “Pha, 16.2 months vs 14.2 months 097 0875 Probability of overall survival + Censored 0 6 12 18 24 30 Months patientforward” GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor T

  7. Slide 7: Confidential © 2025 Novocure GmbH

    Confidential © 2025 Novocure GmbH

  8. Slide 8: Confidential © 2024 Novocure © 2025 GmbH Novocure GmbH 8

    Confidential © 2024 Novocure © 2025 GmbH Novocure GmbH 8

  9. Slide 9: Confidential © 2024 Novocure © 2025 GmbH Novocure GmbH 9

    Confidential © 2024 Novocure © 2025 GmbH Novocure GmbH 9

  10. Slide 10: Appendix

    novecure’ appendix patientforward’

  11. Slide 11: Adjusted EBITDA reconciliation

    novecure’ adjusted EBITDA reconciliation Adjusted EBITDA is a non-GAAP measurement of earnings before interest, taxes, depreciation, amortization and share-based compensation. We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare

  12. Slide 12: © 2025 Novocure GmbH 12

    • • • • • • • • © 2025 Novocure GmbH 12

  13. Slide 13: © 2025 Novocure GmbH 13

    • • • • • • • • • • • • • • © 2025 Novocure GmbH 13

Novocure — Q2 2025 Earnings Presentation on 6ix